• TSH Biopharm announced today (12/6) that ”The ctDNA and CTC Cancer Monitoring Liquid Biopsy Platform” is awarded for the 16th National Innovation Prize in Entrepreneur Category.

  • The value of liquid biopsy technology rises while the more precision therapies developed and the demand of real-time cancer monitoring grows in the past years. In the beginning of the year, General Manager of TSH, Grace Yang launched a dual-engine strategy, expand the core expertise in the field of chronic diseases to severe chronic diseases. TSH Biopharm steps into the cancer diagnosis business through investing in CellMax, and integrates the liquid biopsy platform into the current cancer and chronic disease business. TSH now is able to fulfill the medical need from healthy peoples, patients, and medical doctors. Our cancer liquid biopsy product portfolio includes the high resolution hereditary risk in cancer, the clinical proved cancer gene diagnosis, and multiple cancer diagnosis perform in CAP certified Laboratory, and this product portfolio supports medical doctors all the way from the early detection, treatment decision support, and to the monitoring of disease progression. All these products has been acknowledged by Medical Centers, and be marketed not just in Taiwan but also other countries in Asia. TSH Biopharm is expecting to be the one to offer the total solution for medical doctors and patients.